Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study

被引：0

作者：

Schreiber, S. ^{[1
]}

Reinisch, W. ^{[2
]}

Nguyen, D. ^{[3
]}

Guerin, T. ^{[4
]}

Kierkus, J. ^{[5
]}

Rozpondek, P. ^{[6
]}

Bourdet, D. ^{[3
]}

Abhyankar, B. ^{[7
]}

Peyrin-Biroulet, L. ^{[8
]}

机构：

[1] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Internal Med I, Kiel, Germany

[2] Med Univ Vienna, Dept Internal Med III, Vienna, Austria

[3] Theravance Biopharma Inc, Res & Dev, San Francisco, CA USA

[4] Theravance Biopharma Ireland Ltd, Res & Dev, Dublin, Ireland

[5] Childrens Mem Hlth Inst, Dept Gastroenterol, Warsaw, Poland

[6] Krakow Med Ctr, Krakow, Poland

[7] Theravance Biopharma Ireland Ltd, Clin Dev, Dublin, Ireland

[8] Univ Lorraine, Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P375

引用

页码：505 / 507

页数：3